Redeye provides an update following Episurf Medical’s Q3 2025 report. The report was relatively undramatic, with sales in line with our estimates, but with a better-than-expected cost reduction effect from the restructuring initiatives announced in early Q3. The report also showed a 111% growth in the US customer base. Following the report, we have made slight adjustments to our short-term estimates. We reiterate our fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/